APA (7th ed.) Citation

DC, F., F, T., A, O., P, D., WG, F., & WG, P. (2022). Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS pathogens, 18(6), e1010547. https://doi.org/10.1371/journal.ppat.1010547

Chicago Style (17th ed.) Citation

DC, Files, Tacke F, O'Sullivan A, Dorr P, Ferguson WG, and Powderly WG. "Rationale of Using the Dual Chemokine Receptor CCR2/CCR5 Inhibitor Cenicriviroc for the Treatment of COVID-19." PLoS Pathogens 18, no. 6 (2022): e1010547. https://doi.org/10.1371/journal.ppat.1010547.

MLA (9th ed.) Citation

DC, Files, et al. "Rationale of Using the Dual Chemokine Receptor CCR2/CCR5 Inhibitor Cenicriviroc for the Treatment of COVID-19." PLoS Pathogens, vol. 18, no. 6, 2022, p. e1010547, https://doi.org/10.1371/journal.ppat.1010547.